Merck & Co., Inc.

Key catalysts

• Oncology franchise growth

  Continued oncology demand and new indications can sustain growth while Merck expands the franchise beyond its established uses.

• New product contributions

  Increasing contributions from newer medicines across cardiometabolic, respiratory, and HIV markets can diversify growth beyond the largest established products.

• Late-stage pipeline readouts

  A robust period of Phase 3 readouts and regulatory milestones could validate Merck's efforts to build a broader set of future growth drivers.

Principal risks

• Keytruda concentration

  Merck remains highly dependent on Keytruda, making future patent expiry, competition, and the pace of portfolio diversification material risks.

• Vaccine demand pressure

  Declines in vaccines, including demand pressure affecting Gardasil, can offset gains in oncology and newer launches.

• Business-development charges

  Large acquisition-related charges and continuing development investment can create earnings volatility before acquired pipeline assets generate returns.

For the quarter ended March 31, 2026, Merck reported sales growth supported by oncology, animal health, and newer launches; acquisition charges produced a quarterly loss, while management increased its full-year sales and non-GAAP EPS outlook ranges.

Valuation interpretation

• A durable valuation case requires newer products and late-stage assets to reduce dependence on Keytruda before its loss of exclusivity.
• Pipeline breadth supports strategic optionality, but acquisition spending and uncertain clinical conversion justify a disciplined execution discount.